Pharmacogenetics in randomized controlled trials: Considerations for trial design

Pharmacogenomics

Volumn 12, Issue 10, 2011, Pages 1485-1492

  Van Der Baan, Frederieke H ^a,b   Klungel, Olaf H ^a,b   Egberts, Antoine C G ^a,b   Leufkens, Hubert G ^b,c   Grobbee, Diederick E ^a   Roes, Kit C B ^a   Knol, Mirjam J ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c MEDICINES EVALUATION BOARD   (Netherlands)

Author keywords

clinical trial; evidence; genotype; pharmacogenetics; pharmacogenomics; study design

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; CETUXIMAB; PACLITAXEL; PLACEBO; TAMOXIFEN;

BREAST CANCER; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; DRUG RESPONSE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; INHERITANCE; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; METHODOLOGY; PATIENT CARE; PHARMACOGENETICS; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH SUBJECT; REVIEW; STATISTICAL ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; WILD TYPE;

GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TRANSLATIONAL MEDICAL RESEARCH;

EID: 80054933011     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.95     Document Type: Review

References (45)

1. Sheffield LJ, Phillimore HE. Clinical use of pharmacogenomic tests in 2009. Clin. Biochem. Rev. 30(2), 55-65 (2009).
2. Becquemont L. Pharmacogenomics of adverse drug reactions: practical applications and perspectives. Pharmacogenomics 10(6), 961-969 (2009).
3. Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N. Engl. J. Med. 358(6), 637-639 (2008). (Pubitemid 351214293)
4. Corkindale D, Ward H, McKinnon R. Low adoption of pharmacogenetic testing: an exploration and explanation of the reasons in Australia. Pers. Med. 4(2), 191-199 (2007). (Pubitemid 46845899)
5. Teutsch SM, Bradley LA, Palomaki GE et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet. Med. 11(1), 3-14 (2009).
6. Recommendations from the EGAPP Working Group. Testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet. Med. 9(12), 819-825 (2007).
7. Smits KM, Schouten JS, Smits LJ, Stelma FF, Nelemans P, Prins MH. A review on the design and reporting of studies on drug-gene interaction. J. Clin. Epidemiol. 58(7), 651-654 (2005). (Pubitemid 40797893)
8. Little J, Sharp L, Khoury MJ, Bradley L, Gwinn M. The epidemiologic approach to pharmacogenomics. Am. J. Pharmacogenomics 5(1), 1-20 (2005). (Pubitemid 40803828)
9. Kirchheiner J, Fuhr U, Brockmoller J. Pharmacogenetics-based therapeutic recommendations-ready for clinical practice? Nat. Rev. Drug Discov. 4(8), 639-647 (2005). (Pubitemid 41149757)
10. Serretti A, Kato M, Kennedy JL. Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics J. 8(2), 90-100 (2008). (Pubitemid 351411545)
11. Bromley CM, Close S, Cohen N et al. Designing pharmacogenetic projects in industry: practical design perspectives from the Industry Pharmacogenomics Working Group. Pharmacogenomics J. 9(1), 14-22 (2009).
12. Baker SG , Sargent DJ. Designing a randomized clinical trial to evaluate personalized medicine: a new approach based on risk prediction. J. Natl Cancer Inst. 102(23), 1756-1759 (2010).
13. Stingl Kirchheiner JC , Brockmoller J. Why, when, and how should pharmacogenetics be applied in clinical studies?: current and future approaches to study designs. Clin. Pharmacol. Ther. 89(2), 198-209 (2011).
14. Frueh FW. Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine. Pharmacogenomics 10(7), 1077-1081 (2009).
15. Wegman P, Vainikka L, Stal O et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res. 7(3), R284-R290 (2005).
16. Sherva R, Ford CE, Eckfeldt JH, Davis BR, Boerwinkle E, Arnett DK. Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: the genetics of hypertension associated treatment study. Stroke 42(2), 330-335 (2011).
17. Khambata-Ford S, Harbison CT, Hart LL et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a Phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 28(6), 918-927 (2010).
18. Mega JL, Close SL, Wiviott SD et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360(4), 354-362 (2009).
19. Yasar U, Bennet AM, Eliasson E et al. Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics 13(12), 715-720 (2003). (Pubitemid 38429249)
20. Groenwold RH, Donders AR, van der Heijden GJ, Hoes AW, Rovers MM. Confounding of subgroup analyses in randomized data. Arch. Intern. Med. 169(16), 1532-1534 (2009).
21. Vanderweele TJ, Knol MJ. Interpretation of subgroup analyses in randomized trials: heterogeneity versus secondary interventions. Ann. Intern. Med. 154(10), 680-683 (2011).
22. Davey Smith G, Ebrahim S. What can mendelian randomisation tell us about modifiable behavioural and environmental exposures? BMJ 330(7499), 1076-1079 (2005). (Pubitemid 40646565)
23. Wang SJ, O'Neill RT, Hung HJ. Statistical considerations in evaluating pharmacogenomics-based clinical effect for confirmatory trials. Clin. Trials 7(5), 525-536 (2010).
24. Kemmeren JM, Algra A, Meijers JC et al. Effect of second-and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. Blood 103(3), 927-933 (2004). (Pubitemid 38129552)
25. Johnson BA, Ait-Daoud N, Seneviratne C et al. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am. J. Psychiatry 168(3), 265-275 (2011).
26. Preskorn S, Patroneva A, Silman H et al. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J. Clin. Psychopharmacol. 29(1), 39-43 (2009).
27. Murphy MP, Beaman ME, Clark LS et al. Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a Phase III clinical trial. Pharmacogenetics 10(7), 583-590 (2000).
28. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001). (Pubitemid 32222155)
29. Mulder H, Heerdink ER, van Iersel EE, Wilmink FW, Egberts AC. Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study. Ann. Pharmacother. 41(3), 408-413 (2007). (Pubitemid 46536030)
30. Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J. Adaptive designs in clinical drug development-an Executive Summary of the PhRMA Working Group. J. Biopharm. Stat. 16(3), 275-283 (2006).
31. Swen JJ, Wilting I, de Goede AL et al. Pharmacogenetics: from bench to byte. Clin. Pharmacol. Ther. 83(5), 781-787 (2008). (Pubitemid 351556025)
32. Mallal S, Phillips E, Carosi G et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358(6), 568-579 (2008).
33. Ito Y, Nagasaki K, Miki Y et al. Prospective randomized Phase II study determines the clinical usefulness of genetic biomarkers for sensitivity to primary chemotherapy with paclitaxel in breast cancer. Cancer Sci. 102(1), 130-136 (2011).
34. Schelleman H, Chen J, Chen Z et al. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin. Pharmacol. Ther. 84(3), 332-339 (2008).
35. Anderson JL, Horne BD, Stevens SM et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116(22), 2563-2570 (2007). (Pubitemid 350179221)
36. van Schie RM, Wadelius MI, Kamali F et al. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 10(10), 1687-1695 (2009).
37. Perlis RH, Patrick A, Smoller JW, Wang PS. When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology 34(10), 2227-2236 (2009).
38. Serretti A, Olgiati P, Bajo E, Bigelli M, De Ronchi D. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. World J. Biol. Psychiatry DOI: 10.3109/15622975.2011. 572998 (2011) (Epub ahead of print).
39. Rodriguez-Antona C, Gurwitz D, de LJ et al. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies. Pharmacogenomics 10(4), 685-699 (2009).
40. Farahani P, Levine M, Gaebel K, Thabane L. Clinical data gap between Phase III clinical trials (pre-marketing) and Phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis. Can. J. Clin. Pharmacol. 12(3), e254-e263 (2005). (Pubitemid 43097168)
41. Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am. J. Psychiatry 159(3), 469-473 (2002). (Pubitemid 34184745)
42. Lesko LJ, Zineh I, Huang SM. What is clinical utility and why should we care? Clin. Pharmacol. Ther. 88(6), 729-733 (2010).
43. Woodcock J, Lesko LJ. Pharmacogenetics-tailoring treatment for the outliers. N. Engl. J. Med. 360(8), 811-813 (2009).
44. Meyboom RH, Lindquist M, Egberts AC. An ABC of drug-related problems. Drug Saf. 22(6), 415-423 (2000). (Pubitemid 30386460)
45. Vandenbroucke JP , Psaty BM. Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects. JAMA 300(20), 2417-2419 (2008).